{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:01:30Z","timestamp":1791561690059,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T00:00:00Z","timestamp":1376697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1245\/s10434-013-3217-x","type":"journal-article","created":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T14:31:12Z","timestamp":1376663472000},"page":"4289-4297","source":"Crossref","is-referenced-by-count":90,"title":["A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial"],"prefix":"10.1245","volume":"20","author":[{"given":"Marc","family":"Ychou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Rivoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thezenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Quenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Robert","family":"Delpero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rebischung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Letoublon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosine","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Desseigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,17]]},"reference":[{"key":"3217_CR1","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1245\/s10434-009-0492-7","volume":"16","author":"S Benoist","year":"2009","unstructured":"Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009;16:2385\u201390.","journal-title":"Ann Surg Oncol."},{"key":"3217_CR2","unstructured":"International registry of liver metastases of colorectal cancer. http:\/\/www.livermetsurvey.org\/International ."},{"key":"3217_CR3","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2006.05.8404","volume":"24","author":"G Poston","year":"2006","unstructured":"Poston G, Adam R, Vauthey JN. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer? J Clin Oncol. 2006;24:2702\u20136.","journal-title":"J Clin Oncol."},{"key":"3217_CR4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdi246","volume":"16","author":"G Folprecht","year":"2005","unstructured":"Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311\u20139.","journal-title":"Ann Oncol."},{"key":"3217_CR5","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","volume":"27","author":"R Adam","year":"2009","unstructured":"Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829\u201335.","journal-title":"J Clin Oncol."},{"key":"3217_CR6","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2006.07.9236","volume":"24","author":"SR Alberts","year":"2006","unstructured":"Alberts SR. Evolving role of chemotherapy in resected liver metastases. J Clin Oncol. 2006;24:4952\u20133.","journal-title":"J Clin Oncol."},{"key":"3217_CR7","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/annonc\/mdh217","volume":"15","author":"C Pozzo","year":"2004","unstructured":"Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933\u20139.","journal-title":"Ann Oncol."},{"key":"3217_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000138352","volume":"74","author":"M Ducreux","year":"2008","unstructured":"Ducreux M, Raoul JL, Marti P, et al. High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology. 2008;74:17\u201324.","journal-title":"Oncology."},{"key":"3217_CR9","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0959-8049(01)00068-5","volume":"37","author":"F Maindrault-Goebel","year":"2001","unstructured":"Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer. 2001;37:1000\u20135.","journal-title":"Eur J Cancer."},{"key":"3217_CR10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.2005.05.082","volume":"23","author":"J Taieb","year":"2005","unstructured":"Taieb J, Artru P, Paye F, et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol. 2005;23:502\u20139.","journal-title":"J Clin Oncol."},{"key":"3217_CR11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdg119","volume":"14","author":"M Ychou","year":"2003","unstructured":"Ychou M, Conroy T, Seitz JF, et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin\/5-fluorouracil every 2\u00a0weeks in patients with advanced solid tumors. Ann Oncol. 2003;14:481\u20139.","journal-title":"Ann Oncol."},{"key":"3217_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00280-007-0588-3","volume":"62","author":"M Ychou","year":"2008","unstructured":"Ychou M, Viret F, Kramar A et al. Tritherapy with fluorouracil\/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62:195\u2013201.","journal-title":"Cancer Chemother Pharmacol."},{"key":"3217_CR13","doi-asserted-by":"crossref","unstructured":"Rivoire M, Thezenas S, Rebischung C, et al. Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP). J Clin Oncol. 2008;26(Suppl; abstr 4075).","DOI":"10.1200\/jco.2008.26.15_suppl.4075"},{"key":"3217_CR14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1477-7819-9-154","volume":"9","author":"N Ismaili","year":"2011","unstructured":"Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011;9:154.","journal-title":"World J Surg Oncol."},{"key":"3217_CR15","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ejca.2006.04.012","volume":"42","author":"E Cutsem Van","year":"2006","unstructured":"Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212\u201321.","journal-title":"Eur J Cancer."},{"key":"3217_CR16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","volume":"371","author":"B Nordlinger","year":"2008","unstructured":"Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007\u201316.","journal-title":"Lancet."},{"key":"3217_CR17","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","volume":"24","author":"JN Vauthey","year":"2006","unstructured":"Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065\u201372.","journal-title":"J Clin Oncol."},{"key":"3217_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000193603.26265.c3","volume":"243","author":"M Karoui","year":"2006","unstructured":"Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1\u20137.","journal-title":"Ann Surg."},{"key":"3217_CR19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jamcollsurg.2011.05.001","volume":"213","author":"A Brouquet","year":"2011","unstructured":"Brouquet A, Vauthey JN, Contreras CM, et al. Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. J Am Coll Surg. 2011;213:62\u20139; discussion 69\u201371.","journal-title":"J Am Coll Surg."},{"key":"3217_CR20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","volume":"11","author":"G Folprecht","year":"2010","unstructured":"Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38\u201347.","journal-title":"Lancet Oncol."},{"key":"3217_CR21","doi-asserted-by":"crossref","unstructured":"Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715\u201322, discussion 722\u20134.","DOI":"10.1097\/01.sla.0000160703.75808.7d"},{"key":"3217_CR22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/SLA.0b013e31818a07f1","volume":"248","author":"RJ Haas de","year":"2008","unstructured":"de Haas RJ, Wicherts DA, Flores E, et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248:626\u201337.","journal-title":"Ann Surg."},{"key":"3217_CR23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","journal-title":"N Engl J Med."},{"key":"3217_CR24","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408\u201317.","journal-title":"N Engl J Med."},{"key":"3217_CR25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663\u201371.","journal-title":"J Clin Oncol."},{"key":"3217_CR26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1470-2045(10)70175-3","volume":"11","author":"G Masi","year":"2010","unstructured":"Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845\u201352.","journal-title":"Lancet Oncol."},{"key":"3217_CR27","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1634\/theoncologist.2011-0141","volume":"16","author":"E Assenat","year":"2011","unstructured":"Assenat E, Desseigne F, Thezenas S, et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist. 2011;16:1557\u201364.","journal-title":"Oncologist."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-3217-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-013-3217-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-3217-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:25:12Z","timestamp":1646353512000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-013-3217-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,17]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3217"],"URL":"https:\/\/doi.org\/10.1245\/s10434-013-3217-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,17]]}}}